Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Pharmacokinetics of BPI-7711 in Healthy Male Subjects
NCT04135820Phase 1Completed
- Sponsor
- Beta Pharma
- Start
- Dec 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rezivertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Beta Pharma. Primary endpoints: Maximum Plasma Concentration at Day 15 and Area Under the Curve (0-last) at Day 15. Started Dec 2019; status: completed.
02
Drugs
rezivertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04135820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04135820.